These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34990583)
1. A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2. Yuan Y; Zhang X; Chen R; Li Y; Wu B; Li R; Zou F; Ma X; Wang X; Chen Q; Deng J; Zhang Y; Chen T; Lin Y; Yan S; Zhang X; Li C; Bu X; Peng Y; Ke C; Deng K; Pan T; He X; Zhang Y; Zhang H Cell Rep; 2022 Jan; 38(3):110256. PubMed ID: 34990583 [TBL] [Abstract][Full Text] [Related]
2. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446 [TBL] [Abstract][Full Text] [Related]
3. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. Jangra S; Landers JJ; Rathnasinghe R; O'Konek JJ; Janczak KW; Cascalho M; Kennedy AA; Tai AW; Baker JR; Schotsaert M; Wong PT Front Immunol; 2021; 12():729189. PubMed ID: 34603303 [TBL] [Abstract][Full Text] [Related]
4. Interferon-armed RBD dimer enhances the immunogenicity of RBD for sterilizing immunity against SARS-CoV-2. Sun S; Cai Y; Song TZ; Pu Y; Cheng L; Xu H; Sun J; Meng C; Lin Y; Huang H; Zhao F; Zhang S; Gao Y; Han JB; Feng XL; Yu DD; Zhu Y; Gao P; Tang H; Zhao J; Zhang Z; Yang J; Hu Z; Fu YX; Zheng YT; Peng H Cell Res; 2021 Sep; 31(9):1011-1023. PubMed ID: 34267349 [TBL] [Abstract][Full Text] [Related]
5. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724 [TBL] [Abstract][Full Text] [Related]
6. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351. Gu C; Cao X; Wang Z; Hu X; Yao Y; Zhou Y; Liu P; Liu X; Gao G; Hu X; Zhang Y; Chen Z; Gao L; Peng Y; Jia F; Shan C; Yu L; Liu K; Li N; Guo W; Jiang G; Min J; Zhang J; Yang L; Shi M; Hou T; Li Y; Liang W; Lu G; Yang C; Wang Y; Xia K; Xiao Z; Xue J; Huang X; Chen X; Ma H; Song D; Pan Z; Wang X; Guo H; Liang H; Yuan Z; Guan W; Deng SJ MAbs; 2021; 13(1):1930636. PubMed ID: 34097570 [TBL] [Abstract][Full Text] [Related]
7. Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants. Fan S; Xiao K; Li D; Zhao H; Zhang J; Yu L; Chang P; Zhu S; Xu X; Liao Y; Ji T; Jiang G; Yan D; Zeng F; Duan S; Xia B; Wang L; Yang F; He Z; Song Y; Cui P; Li X; Zhang Y; Zheng B; Zhang Y; Xu W; Li Q Emerg Microbes Infect; 2022 Dec; 11(1):212-226. PubMed ID: 34931939 [TBL] [Abstract][Full Text] [Related]
8. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119 [TBL] [Abstract][Full Text] [Related]
9. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity. Scaglione A; Opp S; Hurtado A; Lin Z; Pampeno C; Noval MG; Thannickal SA; Stapleford KA; Meruelo D Front Immunol; 2021; 12():719077. PubMed ID: 34394127 [TBL] [Abstract][Full Text] [Related]
10. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Sulbaran G; Maisonnasse P; Amen A; Effantin G; Guilligay D; Dereuddre-Bosquet N; Burger JA; Poniman M; Grobben M; Buisson M; Dergan Dylon S; Naninck T; Lemaître J; Gros W; Gallouët AS; Marlin R; Bouillier C; Contreras V; Relouzat F; Fenel D; Thepaut M; Bally I; Thielens N; Fieschi F; Schoehn G; van der Werf S; van Gils MJ; Sanders RW; Poignard P; Le Grand R; Weissenhorn W Cell Rep Med; 2022 Feb; 3(2):100528. PubMed ID: 35233549 [TBL] [Abstract][Full Text] [Related]
13. A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge. Jiang W; Shi L; Cai L; Wang X; Li J; Li H; Liang J; Gu Q; Ji G; Li J; Liu L; Sun M Cell Rep; 2021 Dec; 37(11):110112. PubMed ID: 34863353 [TBL] [Abstract][Full Text] [Related]
14. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J Front Immunol; 2021; 12():824728. PubMed ID: 35154086 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses. Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896 [TBL] [Abstract][Full Text] [Related]
16. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. Zhou R; Wang P; Wong YC; Xu H; Lau SY; Liu L; Mok BW; Peng Q; Liu N; Woo KF; Deng S; Tam RC; Huang H; Zhang AJ; Zhou D; Zhou B; Chan CY; Du Z; Yang D; Au KK; Yuen KY; Chen H; Chen Z EBioMedicine; 2022 Jan; 75():103762. PubMed ID: 34942445 [TBL] [Abstract][Full Text] [Related]
17. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates. Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829 [TBL] [Abstract][Full Text] [Related]
18. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM Front Immunol; 2021; 12():747830. PubMed ID: 34858404 [TBL] [Abstract][Full Text] [Related]
19. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation. Jeong H; Choi YM; Seo H; Kim BJ Front Immunol; 2021; 12():637654. PubMed ID: 33732258 [TBL] [Abstract][Full Text] [Related]